Aptevo details warrant terms as mipletamig shows 79% TP53-AML remission, $8.3M cashNov 17Clinical readoutAptevo TherapeuticsAscentage Pharma Group InternationalUpdated
Cullinan reports Q3 2026 results, flags December CLN-978 data and zipalertinib NDA progressNov 10Quarterly updateBlossomHill TherapeuticsCLN-978
Roche registers giredestrant Phase 3 trial; six other studies updateNov 6Weekly roundup, 16 itemsAbbViealectinibUpdated
Syndax reports Q3 2026 results, 90% Revuforj revenue growth, CFO transitionNov 2Quarterly updaterevumenibSyndax Pharmaceuticals Inc
Wave Life Sciences details Q3 2026 progress on WVE-006, WVE-007, WVE-008 pipelineOct 28Quarterly updateBristol Myers SquibbEli LillyUpdated
Sanofi's NKCE trial SAR443579 in AML halted early; results posted for terminated studyOct 23Weekly roundup, 6 itemsBayerdiclofenac
BeOne Medicines registers Phase 1 trial of BG-T0050 in DLBCL and other B-cell cancersOct 21Weekly roundup, 5 itemsazacitidineBeiGene
MD Anderson trial of azacitidine plus venetoclax maintenance in AML stopped for low enrollmentOct 16Trial updateazacitidineRoche
BeOne registers pediatric trial of sonrotoclax in relapsed AML and B-cell ALLAug 18Trial updateBeiGenesonrotoclax
Aptevo reports frontline AML data for mipletamig, targets Phase 2 talks in early 2027Aug 14Quarterly updateAptevo Therapeutics
Kura Oncology posts $9.1 million in KOMZIFTI revenue in second quarter of 2026Aug 12Quarterly updateKura Oncology, Inc.ziftomenib
Cullinan reports Q2 2026 results, outlines T cell engager trial timelinesAug 6Quarterly updateCullinan Therapeutics Inc.
Syndax reports 2Q26 revenue growth, details EGFR and menin inhibitor pipeline additionsAug 4Quarterly updaterevumenibSyndax Pharmaceuticals Inc
Cullinan Therapeutics registers Phase 1b trial of CLN-049 with azacitidine, venetoclax in AMLJul 23Trial updateazacitidineCLN-049